Compare ClearPoint Neuro Inc (CLPT) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Banco Santander SA — how do they compare? ClearPoint Neuro Inc trades at $15.06 (market cap $454.21M), while Banco Santander SA trades at $14.81 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 465.9× ClearPoint Neuro Inc's market cap, and Banco Santander SA pays a 1.89% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SAN | |
|---|---|---|
Market Cap | $454.21M | $211.63B |
Sector | Health | Financials |
52-Week High | $29.60 | $14.71 |
52-Week Low | $8.66 | $9.37 |
Enterprise Value | $488.79M | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Santander (SAN) trades at $14.80, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a 26.25% net income margin and a P/E of 14.4. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, expected to close in August 2026, which may enhance its US market presence.
The outlook is positive, supported by analyst consensus (64% buy ratings) and record profitability. Key risks include volatile cash flows, with negative net cash flow in 2024, and integration challenges from the Webster deal. Revenue growth remains a catalyst, but investors should monitor execution risks and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
